key: cord-0974287-sqgjnrwb
authors: Mori, Mattia; Capasso, Clemente; Carta, Fabrizio; Donald, William a; Supuran, Claudiu T
title: A deadly spillover: SARS-CoV-2 outbreak
date: 2020-04-29
journal: Expert Opin Ther Pat
DOI: 10.1080/13543776.2020.1760838
sha: 1c61a0251513ee112ce9fbf401b86b4013742d17
doc_id: 974287
cord_uid: sqgjnrwb

nan

of CoV that can be used in the current outbreak as well as in future occurrences are in exceedingly high demand but are not available.

How could this happen, considering the horrifying warning signals from the previous two outbreaks, SARS in 2002 SARS in -2003 and MERS shortly thereafter? Especially considering the publication in 2012 of the excellent book by David Quammen, Spillover: Animal Infections and the Next Human Pandemic [8] , in which the current global crisis was predicted. The answer is unfortunately rather simple: all of us, including scientists, governments, pharmaceutical companies, and laypeople, have a tremendous responsibility.

Scientists have continued to investigate CoV despite having limited resources. Funding has been limited in CoV research likely because the previous two outbreaks were resolved with few casualties [5, 6] . However, based on such pioneering work, we now know a lot about genetics, molecular biology, and the lifecycles of these pathogens. Indeed, SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA beta-coronavirus. These viruses mutate very rapidly since RNA viruses make mistakes during RNA replication for the lack of the errorcorrection mechanisms of the cells involved in copying DNA. Any of these mutations can confer new properties, including the ability to infect new types of cells, or even new organisms and thus to determine the spillover. Like SARS-CoV and MERS-CoV, its genome encodes for non-structural proteins (including 3-chymotrypsin-like protease, also known as main protease, MP; papain-like protease, PLP; helicase; and RNA-dependent RNA polymerase, RdRp) ( Figure 1 ). Some structural proteins (such as the spike glycoprotein) and accessory proteins are also present in the genomes of all CoVs. In this genomic area, coronaviruses are subjected to many mutations, which allow the virus evolution, as well as their potential in evading the response of the immune system, and the jumping from animal to human species.

The genetic material of the virus is transcribed into two viral polypeptides, of 490 kDa and 790 kDa, respectively, which are subsequently co-translationally cleaved into mature nonstructural proteins (Nsps) through the activity of two proteases encoded in the 5′ region of ORF1: PLP and MP ( Figure 1 ). The latter protein has a dominant role in the post-translational processing of the replicase polyprotein. The MPs of various CoV contain similar substrate-binding pockets, usually with the requirement for Gln at position P1 and a preference for leucine/methionine at the P2 sub-pocket (P1 and P2 are the amino acid residues in the substrate undergoing cleavage in the N-terminal direction from the cleaved bond). Both PLP and MP are cysteine proteases: MP is a dimer with a Cys-His dyad at the active site, whereas PLP is a monomer with a Cys-His-Glu canonical catalytic triad. The MP of SARS-CoV-2 has been crystallized recently (and PDB codes released) [9] [10] [11] [12] . Due to the crucial role that these proteases play in the life cycle of the virus, their inhibition may have a potent antiviral effect [13] [14] [15] [16] .

Furthermore, there is a rather relevant homology between the pair of the two proteases in the three CoV mentioned above, which produced epidemic outbreaks in humans ( Figures. 2-3 ), which could be used to target such proteins by designing specific inhibitors. Both PLP and MP of SARS-CoV-2, SARS-CoV, and MERS-CoV have, in fact, a quite conserved amino acid sequence, which means that presumably effective inhibitors for one of them may act efficaciously for all three.

Thus, our knowledge regarding the biochemical machinery of these viruses (exemplified here with the proteases, but the same is valid for the helicase and the polymerase) is rather detailed. Still, it was not translated to the clinics due to the lack of interest from the drug companies, as discovering drugs for a disease that affects a limited Figure 1 . Open reading frame 1 (ORF1) genomic organization of SARS-CoV-2. In the orange boxes, the four enzymes that might be targeted by antiviral drugs: papain-like protease (PLP), main protease (MP), RNA-dependent RNA polymerase (RdRp) and helicase. number of people (as was the case with SARS and MERS) is not costeffective. However, the current outbreak proves how wrong we were. Antivirals, which could be used to treat COVID-19 patients, would probably make the crucial difference in the current pandemic. The development of strategic drugs for such pandemic outbreaks should, from now on, not be left only in the hands of big pharma, but industrial countries (or WHO) should fund programs to develop such therapies in the interests of public health and the global economy. There are some recent anecdotal reports on the repurposing of some antivirals developed for other viruses, such as the human immunodeficiency virus-1 (HIV-1) protease inhibitors lopinavir and ritonavir [17] , disulfiram, which is known to inhibit SARS-CoV proteases [18] as well as some newer agents, which are shown in Figure 4 [19] . Among them, Remdesivir is a nucleoside analog acting as a polymerase inhibitor that is in clinical development for the treatment of Ebola [20] , which seems to have some efficacy for the management of COVID-19 [21] . However, all these are relatively desperate options due to the lack of specific agents targeting CoV.

There are several proposals for vaccine candidates [22] based on the mechanism used by SARS-CoV-2 to infect T lymphocytes [23] or approaches which contemplate the use of fusion inhibitors [24] , targeting the spike protein of the virus, but the development of such therapeutics may take longer compared to the classical targets mentioned above. All these data show that the scientific community responded in an exemplary manner to the emergency, but as usual, a voice out of the chorus emerged [25] with irrelevant comments and exaggerations on statistics, as was the case with a dubious analysis of citations and impact factors of the major journals.

Overall, more than half of the world's population is locked down, and a massive number of new cases are reported each day, many more cases remain undiagnosed, and no effective drugs are available. For a species that chooses to name itself Homo sapiens ('wise humans' in Latin), this is probably a time when it is obvious that a more appropriate name should be 'Homo insapiens' (unwise humans). At the end of this emergency, we should dramatically rethink how to manage the environment, the extinction of a considerable number of species with a consequent impoverishment of the biosphere and, last but not least, global warming. The COVID-19 outbreak is another ringing bell announcing how much the decisions our species are currently making are insapiens. 

-I N F C Y M H Q M E L A N G T H T G S A F D G T M Y G A F M D K Q V H Q V Q L T -199 -V S F C Y M H H M E L P T G V H A G T D L E G K F Y G P F V D R Q T A Q A A G T -197 -V S F C Y M H H M E L P T G V H A G T D L E G N F Y G P F V D R Q T A Q A A G T -196 -D K Y C S V N V V A W L Y A A I L N G C A W F V K P N R T S V V S F N E W A L A -

This paper was not funded.

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

A reviewer on this manuscript has disclosed that they acted as a consultant for Abbvie, MSD, Correvio, Pfizer and Angelini, and managed department grants from Gilead Sciences. All other peer reviewers on this manuscript have no relevant financial or other relationships to disclose. 

A novel coronavirus associated with severe acute respiratory syndrome

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission

Three emerging coronaviruses in two decades

A novel coronavirus from patients with pneumonia in China

Coronavirus genomics and bioinformatics analysis

Middle East respiratory syndrome coronavirus transmission

Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2

Spillover: animal infections and the next human pandemic

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

The papain-like protease determines a virulence trait that varies among members of the SARS-coronavirus species

Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

α-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structurebased design, synthesis, and activity assessment

p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1

Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study

a review of candidate therapies for middle East respiratory syndrome from a molecular perspective

a systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Remdesivir as a possible therapeutic option for the COVID-19

Subunit vaccines against emerging pathogenic human Coronaviruses

SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures